News
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals enters discovery and co-development agreement with Scenic Biotech to develop disease-modifying oligonucleotide therapy against a novel drug target
Secarna Pharmaceuticals partners with Scenic Biotech to develop disease-modifying oligonucleotide therapy against novel drug target, leveraging expertise and synergies for new treatments -
COMMUNIQUÉ DE PRESSE
Sky Gold Corp. Announces Completion of Oversubscribed Private Placement and Commencement of Geophysical Surveys and Drilling at Evening Star Property, Nevada
Sky Gold Corp. starts geophysical surveys and diamond drilling at Evening Star Property in Nevada. CEO Mike England excited about Tower Gold target drilling -
-
COMMUNIQUÉ DE PRESSE
SMX's Lean Share Structure Becomes Its Latest Value Driver as It Expands the "Proof as Currency" Platform (NASDAQ:SMX)
SMX (NASDAQ:SMX) announces strategic recapitalization, setting the stage for accelerated growth and value enhancement through optimized share structure and global partnerships -
COMMUNIQUÉ RÉGLEMENTÉ
Chiffre d'Affaires du 1er Semestre de l'exercice 2025/2026
Le Groupe JAJ annonce une croissance exceptionnelle de +27% au 2ème semestre 2025-2026, grâce au succès de ses marques SCHOTT et RIVIERAS. La stratégie RSE du groupe se renforce avec des actions concrètes. Objectif de croissance annuelle à deux chiffres confirmé -
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
Telomir Pharmaceuticals reports new findings on Telomir-1's impact on CASP8 and GSTP1 genes, highlighting potential in cancer therapy through DNA methylation modulation -
-
-
